<DOC>
	<DOC>NCT02940002</DOC>
	<brief_summary>To explore the efficacy and safety of four BAY1003803 formulations by means of a within subject comparison in an open Psoriasis Plaque Test</brief_summary>
	<brief_title>BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Male and female (nonchildbearing potential) volunteer with stable plaquetype psoriasis, but otherwise healthy Age: 1864 years Severe disease within the last 4 weeks prior to the first study drug administration as determined by the investigator Any topical antipsoriatics on plaques potentially to be treated in this trial (including corticosteroids, vitamin D analogues, immunomodulators, retinoids, dithranol and tar, except for salicylic acid (Pretreatment) in the 4 weeks before first treatment and/or planned during the trial, except for allowed topical treatment on the face, ears and scalp Systemic treatment depending on kind of treatment within 4 weeks and 6 months prior and/or planned during the trial Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, e.g. antimalarial drugs, lithium, betablockers or angiotensinconvertingenzyme inhibitors (AEC inhibitors) unless on a stable dose for 3 months before study medication initiation Clinicochemical parameters of clinically significant deviation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Plaque form psoriasis vulgaris</keyword>
</DOC>